We find that serologic reactivity to dengue 1 virus (DENV1) EDIII before ZIKV exposure is associated with increased ZIKV neutralizing titers after exposure. Antibody cloning shows that donors with high ZIKV neutralizing antibody titers have expanded clones of memory B cells that express the same immunoglobulin VH3-23/VK1-5 genes. These recurring antibodies cross-react with DENV1, but not other flaviviruses, neutralize both DENV1 and ZIKV, and protect mice against ZIKV challenge. Structural analyses reveal the mechanism of recognition of the ZEDIII lateral ridge by VH3-23/VK1-5 antibodies. Serologic testing shows that antibodies to this region correlate with serum neutralizing activity to ZIKV. Thus, high neutralizing responses to ZIKV are associated with pre-existing reactivity to DENV1 in humans.
In Brief
Individuals with high neutralizing antibody response against Zika virus have expanded clones of B cells that express the same heavy and light immunoglobulin genes and that are cross-reactive against dengue 1 virus.
SUMMARY
Antibodies to Zika virus (ZIKV) can be protective. To examine the antibody response in individuals who develop high titers of anti-ZIKV antibodies, we screened cohorts in Brazil and Mexico for ZIKV envelope domain III (ZEDIII) binding and neutralization. We find that serologic reactivity to dengue 1 virus (DENV1) EDIII before ZIKV exposure is associated with increased ZIKV neutralizing titers after exposure. Antibody cloning shows that donors with high ZIKV neutralizing antibody titers have expanded clones of memory B cells that express the same immunoglobulin VH3-23/VK1-5 genes. These recurring antibodies cross-react with DENV1, but not other flaviviruses, neutralize both DENV1 and ZIKV, and protect mice against ZIKV challenge. Structural analyses reveal the mechanism of recognition of the ZEDIII lateral ridge by VH3-23/VK1-5 antibodies. Serologic testing shows that antibodies to this region correlate with serum neutralizing activity to ZIKV. Thus, high neutralizing responses to ZIKV are associated with pre-existing reactivity to DENV1 in humans.
INTRODUCTION
Zika virus (ZIKV) infection typically produces mild symptoms consisting of fever, rash, and arthralgia that resolve rapidly, and the infection is also occasionally associated with GuillainBarré syndrome (Lessler et al., 2016; Miner and Diamond, 2017; Weaver et al., 2016) . However, when infection occurs during pregnancy, vertical transmission can lead to a spectrum of devastating neurodevelopmental aberrations, collectively referred to as congenital Zika syndrome. Although the data are still incomplete, infants born to mothers infected with ZIKV during pregnancy carry an up to 42% risk of developing overt clinical or neuroimaging abnormalities (Brasil et al., 2016; Franç a et al., 2016) .
ZIKV belongs to the Flavivirus genus, which includes yellow fever (YFV), West Nile (WNV), and the four serotypes of dengue virus (DENV1-DENV4). These positive-stranded RNA viruses are responsible for considerable morbidity and mortality in the equatorial and subequatorial regions populated by their mosquito vectors (Kramer et al., 2007; Murray et al., 2013; Weaver and Reisen, 2010) . Unlike most other flaviviruses, ZIKV can also be transmitted sexually, and on occasion persists for months (Barzon et al., 2016; Foy et al., 2011; Murray et al., 2017; Suy et al., 2016) .
All flaviviruses display a single envelope protein, E, that is highly conserved between different members of this virus family. The E protein ectodomain consists of three structural domains. Domain I (EDI) contains the N terminus, domain II (EDII) is an extended finger-like structure that includes the dimerization domain and also a pH-sensitive fusion loop that mediates viral fusion in the lysosomes. Finally, domain III (EDIII) is an immunoglobulin-like domain that mediates attachment to target cells (Barba-Spaeth et al., 2016; Dai et al., 2016; Kostyuchenko et al., 2016; Modis et al., 2003; Mukhopadhyay et al., 2005; Rey et al., 1995; Sirohi et al., 2016; Zhang et al., 2004) . Several human neutralizing antibodies targeting different E protein epitopes have been described. Antibodies against the EDIII of flaviviruses are among the most potent neutralizers in this group (Beasley and Barrett, 2002; Crill and Roehrig, 2001 ; Screaton et al., 2015) .
Due to the conserved structural features of the E protein, antibodies that develop in response to infection by one flavivirus may also recognize others (Heinz and Stiasny, 2017) . Cross-reactivity can lead to cross-protection, as first documented by Sabin, who showed experimentally in humans that exposure to DENV1 could provide short-term protection from subsequent challenge with DENV2. In contrast, immunity to the autologous strain was long lasting (Sabin, 1950) . More recently, human monoclonal antibodies to DENV have been shown to cross-neutralize ZIKV, and vice versa (Barba-Spaeth et al., 2016; Stettler et al., 2016; Swanstrom et al., 2016) . However, there is concern that cross-reacting antibodies that fail to neutralize the virus may enhance rather than curb subsequent flavivirus infections (Harrison, 2016; Wahala and Silva, 2011) . In vitro and in vivo experiments in mice suggest that this phenomenon, commonly referred to as antibody-dependent enhancement (ADE), extends to ZIKV (Bardina et al., 2017; Dejnirattisai et al., 2016; Harrison, 2016; Priyamvada et al., 2016) . For this reason, a desirable goal for ZIKV vaccines is to elicit robust and protective antibodies, while avoiding antibodies that bind to the virus but are non-neutralizing and potentially enhancing. Doing so requires a detailed understanding of the neutralizing antibody response to ZIKV.
Several human antibodies to ZIKV have been cloned from convalescent individuals by methods utilizing B cell transformation with Epstein-Barr virus Stettler et al., 2016) . However, individual donors were not selected for high neutralization titers; whether their antibodies are representative of optimal immune responses and how these antibodies might relate to previous flavivirus exposure remains unknown.
Here, we report on the characteristics of the neutralizing antibody responses that developed in individuals with high levels of serum ZIKV neutralizing activity from two independent cohorts after recent ZIKV outbreaks in Brazil and Mexico and on their relationship to previous flavivirus exposure.
RESULTS

Serologic Responses to ZIKV in Brazil and Mexico
Individuals infected with pathogens display a spectrum of antibody responses ranging from low levels of non-neutralizing antibodies to high titers of neutralizing antibodies. To determine whether a population infected with ZIKV also displays a range of antibody responses, we screened 405 individuals living in ZIKV epidemic areas for serum IgG capable of binding to ZIKV E domain III (ZEDIII) ( Figure 1A ).
Nearly three hundred sera were obtained in November 2015, shortly after ZIKV was introduced in Salvador, Brazil, from participants who were enrolled in a prospective study in 2013 The neutralization capacity of selected sera from Mexico (red), Brazil (light red), and control samples obtained in Brazil in 2010 (gray) was determined by a ZIKV luciferase reporter viral particle (RVP) neutralization assay. The reciprocal of the serum dilution that resulted in 50% inhibition compared to RVP alone is reported as the 50% neutralization titer (NT 50 ). The dotted line indicates the lower limit of dilutions that were examined. The five samples below the dotted line have NT 50 values lower than 10 3 . Individuals from whom antibodies were sequenced and cloned are indicated.
from Pau da Lima, an urban slum community within the city (Cardoso et al., 2015; Felzemburgh et al., 2014; Hagan et al., 2016 ). An additional 108 sera were from Santa Maria Mixtequilla, a rural town in Oaxaca, Mexico. ZIKV infections were documented by PCR in Santa Maria Mixtequilla at the time of sample collection in April 2016. Dengue virus (DENV) is endemic at both sites. Sera obtained from the Pau da Lima cohort in 2010 after a DENV outbreak, but before the introduction of ZIKV into Brazil, served as non-ZIKV flavivirus-exposed controls for background reactivity against ZIKV . ZIKV introduction was associated with a broad distribution of serologic reactivity against ZEDIII in both Brazilian and Mexican samples by ELISA ( Figure 1A ). To determine whether serologic reactivity to ZEDIII is associated with ZIKV neutralizing activity, we assessed the top 31 sera (blue symbols in Figure 1A ) for neutralization of luciferaseexpressing reporter viral particles (RVPs) bearing ZIKV structural proteins (see STAR Methods; Figure 1B ). Neutralizing titers, expressed as the reciprocal of the dilution resulting in a 50% reduction of the luciferase signal achieved in the absence of serum (NT 50 ), varied by over 2 logs, indicating a broad range of humoral immune responses to ZIKV ( Figure 1B ).
Human Monoclonal Antibodies to ZIKV
To further characterize the antibody response in six individuals with high neutralizing titers, three from each cohort, we used fluorescently labeled ZEDIII to identify and purify single memory B cells in the peripheral blood ( Figure 2A ). ZEDIII-specific memory B cells were found at frequencies ranging from 0.13%-1.98% of all circulating IgG + memory B cells ( Figure 2A , see STAR Methods). Although the sample size is limited, the frequency of ZEDIII-specific memory B cells did not appear to correlate with either ZEDIII binding or neutralizing activity (Figure 1 ). We conclude that there is significant variability in the frequency of ZEDIII-specific memory B cells in individuals who show serum ZIKV neutralizing activity.
Antibody heavy (IGH) and light (IGL) chain genes were amplified from single purified ZEDIII binding B cells by RT-PCR and sequenced (Scheid et al., 2009; von Boehmer et al., 2016) . Overall, 290 antibodies were identified from the six individuals. As expected based on similar studies on HIV-1 and influenza, nearly one half of all of the antibodies (133) were found in expanded clones that shared the same IGH and IGL variable (IGVH and IGVL) gene segments, and the remaining half were unique (Figure 2B and Tables S1 and S2 ). See also Figure S1 and Tables S1 and S2 .
Memory B cells expressing antibodies composed of VH3-23 paired with VK1-5 were found in five out of the six individuals assayed (red slices in Figure 2B and Figure S1 ). Moreover, VH3-23/VK1-5 was present as an expanded clone in four individuals and was the largest expanded clone in three out of the six individuals. The sequence of the VH3-23/VK1-5 antibodies in the expanded clones was further limited in that the VK1-5 gene segment was always recombined with JK1 ( Figure 2C ). In addition to VH3-23/VK1-5 clones, we also found expanded clones of memory B cells expressing antibodies composed of VH3-23 paired with other IGL genes (VH3-23/VK1-27, VH3-23/ VK3-11 and VH3-23/VK3-20; blue slices in Figure 2B Figure S2B ), which is far lower than that seen in antibodies during chronic HIV-1 infection (Escolano et al., 2017) . Nevertheless, the mutations in anti-ZEDIII antibodies are essential to the binding activity of the antibodies since reversion of the mutations to the predicted germline sequence impaired binding to the antigen ( Figure 3B ).
To determine whether the antibodies cloned from our cohorts cross-react to the EDIII proteins of other flaviviruses, we screened for binding to the four DENV serotypes (DENV1-DENV4), YFV (Asibi and 17D strains), and WNV. We observed five different patterns of cross-reactivity with other flaviviruses ( Figure 3C ). All eight of the VH3-23/VK1-5 antibodies tested cross-reacted with DENV1, but not with the other flaviviruses in our panel ( Figures 3C and 3D ). Other antibodies showed singular cross-reactivity to WNV, or broader reactivity to DENV1-DENV4, or YFV and WNV, and some antibodies were uniquely specific for ZIKV ( Figure 3C ). Similar to ZIKV, mutations in the VH3-23/VK1-5 antibodies were required for optimal binding to DENV1 EDIII since reversion to the predicted germline sequence impaired binding to the DENV1 antigen ( Figure 3D ). We conclude that anti-ZEDIII VH3-23/VK1-5 antibodies crossreact with DENV1 but not with other flaviviruses.
Neutralizing Activity In Vitro and In Vivo
To determine whether the anti-ZEDIII antibodies neutralize ZIKV in vitro, we measured their neutralizing activity in the ZIKV luciferase RVP assay described above. As expected, neutralizing activity varied among the different antibodies ranging from sub-nanogram 50% inhibitory concentrations (IC 50 ) to non-neutralizing (Figures 4A, 4B and S3A) . The most potent antibody, Z004, a member of one of the VH3-23/VK1-5 clones, displayed an IC 50 of 0.7 ng/mL ( Figures 4A and 4B) . Similar results were obtained via a plaque reduction neutralization test (PRNT) using a Puerto Rican strain of ZIKV (IC 50 of 2.2 ng/mL, Figure S3B) . All of the other VH3-23/VK1-5 antibodies tested were also potent neutralizers of ZIKV, with IC 50 values ranging from 0.7-4.6 ng/mL ( Figure 4A ). (C) ZEDIII epitope: EDIII residues contacted by Z006 Fab are highlighted on a surface representation of the EDIII structure. EDIII residues contacted by V H are blue, residues contacted by V L are cyan, and residues making interactions with both V H and V L are dark blue. The E393 ZIKV -K394 ZIKV motif is outlined. Contacts between the Z004 Fab and DENV1 EDIII were less extensive than Z006-ZEDIII contacts, in part because of disorder of the CC 0 loop in DENV1 EDIII (residues 343-349) (STAR Methods).
(legend continued on next page)
Z004 is a member of the VH3-23/VK1-5 family that crossreacts with DENV1. To determine whether Z004 also neutralizes DENV1, we measured its neutralizing activity against DENV1 luciferase RVPs and by flow cytometry using authentic DENV1. We found that Z004 is a potent neutralizer of DENV1 in both assays (IC 50 = 1.6 ng/mL by luciferase assay and IC 50 = 16.4 ng/mL by flow cytometry; Figures 4C and S3C) . Thus, the VH3-23/VK1-5 antibody Z004 binds and neutralizes both ZIKV and DENV1.
To determine whether VH3-23/VK1-5 antibodies also neutralize ZIKV in vivo, we passively transferred Z004 to IFNRA À/À mice one day before or one day after ZIKV infection ( Figure 4D ). In three independent pre-exposure experiments, including a total of 14 mice infected with ZIKV in the presence of control antibody, we found that 93% developed clinical symptoms and 79% succumbed to infection. In contrast, pre-exposure prophylaxis with Z004 resulted in a significant reduction in disease symptoms and mortality. Only 12.5% of the Z004 group developed clinical symptoms and none died (p < 0.0001 for both disease and survival; Figures 4E and S3D) . Similar results were also obtained when the antibody was administered one day after infection (p < 0.0001 for symptoms, p = 0.0027 for survival; Figures 4F and S3D). We conclude that Z004 was protective and significantly reduced both symptoms and mortality when administered either before or after infection. Z004 also displayed a suitable profile of low poly-and auto-reactivity ( Figure S3E ). Thus, VH3-23/VK1-5 antibodies have the potential for further pre-clinical evaluation.
VH3-23/VK1-5 Antibodies Recognize the Lateral Ridge of ZEDIII There are only two contiguous amino acids that are uniquely shared between the EDIIIs of ZIKV and DENV1, and not by DENV2, DENV3, DENV4, WNV, or YF (E393 and K394 in ZIKV, E384 and K385 in DENV1; Figure 4G ). These two amino acids are found in the lateral ridge region of the ZEDIII, which is a region that is associated with virus interaction with cellular receptors (Mukhopadhyay et al., 2005) . To determine whether these two amino acids are essential for interaction between VH3-23/VK1-5 antibodies and ZIKV, we made alanine substitutions in the context of the ZIKV RVPs and tested the recombinant RVPs for sensitivity to Z004-mediated neutralization. Although ZIKV RVPs bearing the E393A substitution remained sensitive to Z004, K394A mutant RVPs were resistant to the antibody ( Figure 4H ). African ZIKV strains differ from others at position 393, carrying aspartic acid at this position. Similar to wild-type Asian/American ZIKV RVPs, African ZIKV RVPs carrying D393 instead of E393 were sensitive to Z004, and Asian/American ZIKV RVPs with an E393D substitution were also efficiently neutralized (Figures 4G and I) . Thus a shared epitope in the lateral ridge region could account for the finding that Z004 neutralizes ZIKV and DENV1, but not other flaviviruses.
Structures of ZIKV Antibody-EDIII Complexes Reveal a Shared Binding Mode
To gain additional insights into the molecular basis of ZEDIII recognition by VH3-23/VK1-5 antibodies, we solved crystal structures of complexes of the antigen-binding fragment (Fab) of two antibodies isolated from different donors, Z006 and Z004, with ZIKV and DENV1 EDIII domains, respectively (Table  S5 ). The Z006 Fab-ZEDIII and Z004 Fab-DENV1 EDIII structures showed a common mode of antigen recognition, as revealed by similar orientations of Fab V H and V L domains when the EDIII domains were superimposed ( Figure 5A ). The orientation of Fab binding for Z006 and Z004 is distinct from orientations in other crystallographically characterized Fab-ZIKV and Fab-DENV1 EDIII complexes ( Figure 5B ). The Z006 epitope extends over much of the EDIII lateral ridge ( Figure 5C ): beyond the E393-K394 ZIKV region, the next largest parts of the interface consist of the N-terminal region of EDIII (residues 305-311 ZIKV ), CC 0 loop residues 350-352 ZIKV , and BC loop residues 333-336 ZIKV . The E393-K394 ZIKV (E384-K385 DENV1 ) motif is central to the interface ( Figure 5C ) and contacts residues within the Fab CDRH3, CDRL3, and CDRL1 loops in both structures ( Figures  5A and 5D-5F ). Despite the antibodies originating from different donors and binding to two different flavivirus EDIIIs, a number of contact interactions occur in both complexes (Table S6) . Specifically, the side chain of residue K394 ZIKV (K385 DENV1 ) occupies a hydrophobic pocket formed by W32 LC and Y91 LC (Z006)/ F91 LC (Z004) and forms a hydrogen (H)-bond with the latter residue's backbone oxygen atom ( Figure 5D ). The side chain of residue E393 ZIKV (E384 DENV1 ) interacts with R96 HC , although this interaction differs somewhat in the two structures: in the Z006 structure, E393 ZIKV forms an H-bond with the Y91 LC hydroxyl and an electrostatic interaction with R96 HC , while for Z004, the side chain of residue F91 LC lacks a hydroxyl group to form an H-bond, and instead the side chain of E384 DENV1 forms a salt bridge with R96 HC ( Figure 5E ). Other common interactions include the side chain of Y58 HC forming an H-bond to the backbone oxygen of L307 ZIKV (M301 DENV1 ) ( Figure 5F ), and the side chain of T93 LC (Z006)/S93 LC (Z004) forming an H-bond to the backbone nitrogen of T335 ZIKV (T329 DENV1 ). Hence, the common mode of recognition involves using equivalent pairwise interactions as well as binding with a similar orientation.
Pre-existing DENV1 Reactivity is Associated with Enhanced ZEDIII Antibody Responses
The existence of VH3-23/VK1-5 antibodies that neutralize both DENV1 and ZIKV and are recurrently found in expanded clones suggests that prior exposure to DENV1 primes the development of protective ZIKV immunity. To examine this possibility, we tested sera obtained at time points before and after introduction of ZIKV in the Pau da Lima community in Salvador, Brazil. As expected, anti-ZEDIII serum IgG reactivity increased significantly between April and November of 2015 ( Figure 6A ). Interestingly, Tables S5 and S6. a similar increase was seen for DENV1, although there was no documented DENV1 outbreak in this area at this time, with only five DENV1 cases reported between September 2014 and July 2016 ( Figure 6A ). In contrast, no significant increase in reactivity was observed for DENV2, DENV3, DENV4, YFV, or WNV EDIIIs ( Figure 6A ). Consistent with the hypothesis that DENV1 primes the subsequent response to ZIKV, we observed a significant positive correlation between DENV1 EDIII-reactive IgG levels pre-ZIKV and ZEDIII-reactive IgG levels post-ZIKV (pseudo-r = 0.48, p < 0.001, Figure 6B ). Together, these data indicate that the exposure to ZIKV boosted the pre-existing DENV1 antibody response, and that individuals with pre-existing antibodies targeting the DENV1 EDIII are more likely to develop high levels of EDIII antibodies upon ZIKV infection.
Lateral Ridge Antibodies Are Associated with ZIKV Neutralization To determine whether antibodies to the lateral ridge region recognized by Z004 contribute to serologic activity against ZIKV in the Pau da Lima cohort, we developed a competition ELISA assay. In this assay, we measured inhibition of biotin-Z004 binding to ZEDIII in order to quantify lateral-ridge-binding antibodies present in serum (see STAR Methods). Paired samples from April 2015 (before ZIKV) and November 2015 (after ZIKV) showed an increase in lateral ridge reactivity after ZIKV introduction (p = 0.0007, Figure 7A ). Levels of antibodies present in the post-ZIKV serum that are capable of blocking Z004 binding to ZEDIII were directly correlated with the overall reactivity of antibodies to ZEDIII (Spearman coefficient, r = 0.7319, p < 0.0001, Figure 7B ), as well as with the increase in reactivity to ZEDIII from prior to after ZIKV (r = 0.8190, p < 0.0001, Figure 7C ). Finally, there was also a significant correlation between ZIKV neutralizing activity and total ZEDIII reactivity (r = 0.5885, p = 0.0012, Figure 7D ), as well as Z004 blocking activity (r = 0.6585, p = 0.0002, Figure 7E ). We conclude that antibodies that block Z004 binding to the lateral ridge make a measurable contribution to the overall serum neutralizing activity to ZIKV in exposed individuals.
DISCUSSION
Previous studies have examined anti-ZIKV antibodies developing in a small number of available individuals Stettler et al., 2016; Wang et al., 2016) . In contrast, we screened sera from more than 400 donors from ZIKV epidemic areas of Mexico and Brazil to select high responders. As expected, serologic reactivity to ZIKV varied greatly among individuals, with neutralization potencies spanning over more than 2 logs. To better understand this activity, we isolated 290 memory B cell antibodies from six individuals with high serum neutralizing activity. The cloning experiments revealed the existence of expanded clones of memory B cells expressing E protein lateral-ridge-specific ZIKV and DENV1 neutralizing VH3-23/VK1-5 antibodies in four of the six individuals. Three separate groups have cloned human anti-ZIKV E protein reactive antibodies Stettler et al., 2016; Wang et al., 2016) . In all, they studied eight individuals and documented 92 antibodies to the E protein. The great majority of these antibodies (79) were obtained by screening supernatants of Epstein-Barr-virus-transformed B lymphocytes for binding to ZIKV, and only a minority (15) were directed to the ZEDIII. Among all of these antibodies, there was only a single expanded clone containing three related VH1-46/VK1-39 antibodies specific for a yet to be determined E epitope. These three antibodies were relatively poor neutralizers (3-257 mg/mL) (Wang et al., 2016) . There was also a single VH3-23/VK1-5 antibody that targeted the ZEDIII and neutralized ZIKV (ZIKV-116), but this antibody appears to be somewhat different than those reported here because it failed to neutralize the African ZIKV strain . Thus, there was no prior indication of a potent dominant neutralizing response to ZIKV.
We found a total of 69 individual VH3-23/VK1-5 memory B cells antibodies in five out of six individuals. In addition to recurring V gene segments, VH3-23/VK1-5 antibodies bear the same IGL J gene, and a limited set of IGH D and J genes. These antibodies are closely related, and they are potent neutralizers with IC 50 values ranging from 0.7-4.6 ng/mL. This variation in activity is likely due to somatic mutations, since predicted germline versions of the VH3-23/VK1-5 antibodies bind to ZEDIII and neutralize the virus only weakly. Thus, not unexpectedly, somatic mutations are required for optimal VH3-23/VK1-5 antibody neutralizing activity.
Recurring antibodies that share the same IGV genes and the same molecular interactions with antigen have not been reported for ZIKV or other flaviviruses, but they have been described in other viral infections, including HIV-1 and influenza. Broadly neutralizing antibodies targeting the CD4 binding site of HIV-1 frequently utilize VH1-2 or VH1-46 genes (Scheid et al., 2011; West et al., 2012) , and broadly neutralizing antibodies to influenza utilize VH1-69 (Laursen and Wilson, 2013; Pappas et al., 2014; Sui et al., 2009; Throsby et al., 2008; Wrammert et al., 2011) . However, in both HIV-1 and influenza, the VH genes can be paired with a collection of different VL genes, a finding that was explained by structural analysis showing that many of the essential contacts made by influenza and HIV-1 antibodies involve variable portions of the IGHV (Ekiert et al., 2009; Pappas et al., 2014; Scheid et al., 2011; Wrammert et al., 2011; Zhou et al., 2010) .
Although the Z004 and Z006 antibodies have CDRH3s and CDRL3s of different lengths, they share a common mode of EDIII binding. Several shared sequence features may be critical for this binding mode. The most suggestive of these is R96 HC . This CDRH3 residue appears to derive from N region addition, thus the different VH3-23/VK1-5 clones do not share this residue due to shared germline genes. Examination of a large collection (n = 44,270) of VH3-23-derived antibody sequences indicates that only 13% have R at position 96 (Rubelt et al., 2012) . However, 68 of 69 of the sequenced VH3-23/VK1-5 clones contain R96. The clones also tend to conserve the germline residues forming the Z004-or Z006-EDIII common interactions: Y58 HC , W32 LC , Y91 LC , and S93 LC .
The requirement for conserved IGHV and IGLV genes in VH3-23/VK1-5 antibodies appears to be explained in part by (B and C) The estimated quantity (mg/mL) of Z004 blocking antibodies in the serum obtained after ZIKV introduction (X axes) was plotted with the overall serum binding activity to ZEDIII (y axis, B), and the change in that individual's serum ZEDIII binding from before to after ZIKV (y axis, C). Binding activity change was determined by subtracting the pre-from the post-ZIKV ELISA relative optical density value (average of two independent measurements). Each dot represents an individual (n = 62, two-tailed Spearman r test). (D and E) Serum neutralization potency expressed as NT 50 versus the overall serum binding activity to ZEDIII (D), or Z004 blocking antibody concentrations in sera (E) obtained after ZIKV introduction are plotted. Each dot represents a serum sample from a single donor (n = 27, two-tailed Spearman r test). Representative of two independent experiments is shown.
interactions involving germline residues. For the light chain, CDRL1 germline residue W32 LC interacts with K394 ZIKV . Few IGLV genes contain W32; the most common of these is VK1-5 (followed by VK1-12, but this gene is several-fold less common than VK1-5). For the heavy chain, residue Y58 HC (present in the VH3-23 germline) makes a contact with EDIII residue 307 ZIKV . Y58 HC is present in $50% of VH germlines, potentially explaining a portion of the restriction. Finally, VH3-23 is among the most frequently used VH genes, as is VK1-5 (Arnaout et al., 2011; DeKosky et al., 2015) . Therefore it is likely that naive B cell precursors carrying DENV1 and ZIKV reactive VH3-23/VK1-5 antibodies would also be common in the preimmune repertoire, making this epitope a particularly attractive vaccine candidate.
VH3-23/VK1-5 antibodies recognize and neutralize both DENV1 and ZIKV, suggesting that clones of VH3-23/VK1-5 producing B cells originally elicited in response to DENV1 were further expanded in response to ZIKV. This prime-boost, or original antigenic sin, hypothesis is supported by two observations. First, pre-existing antibodies to DENV1 EDIII are associated with a higher antibody response to ZEDIII. Second, at the population level, the introduction of ZIKV correlates with an increase in DENV1 EDIII-reactive antibodies at a time when DENV1 was not circulating. Although DENV1 and ZIKV only share 50% amino acid identity in EDIII, they are structurally very similar, particularly in the lateral ridge region that is recognized by VH3-23/VK1-5 ( Figure 5 ). Thus, DENV1 EDIII reactive memory B cells have a significant probability of being cross-reactive to ZEDIII. A primary response to DENV1 would increase the frequency of these ZIKV cross-reactive memory B cells and thereby increase their likelihood of undergoing clonal expansion in response to ZIKV. Consistent with this idea, memory B cells with VH3-23/VK1-5 antibodies represent close to half of all ZEDIII-specific B cell clones in three of the six individuals examined.
Infection by DENV1 confers transient protection to infection by DENV2 (Sabin, 1950 (Sabin, , 1952 . Whether prior DENV1 infection also protects from ZIKV by cross-priming or in other cases enhances infection is unclear (Castanha et al., 2016; Dejnirattisai et al., 2016; Priyamvada et al., 2016; Swanstrom et al., 2016; Wahala and Silva, 2011) . However, the existence of human antibodies to DENV that cross-neutralize or enhance ZIKV in vitro indicates that protection by cross-priming is possible (Barba-Spaeth et al., 2016; Dejnirattisai et al., 2016; Harrison, 2016; Pierson and Graham, 2016; Priyamvada et al., 2016; Stettler et al., 2016; Swanstrom et al., 2016) .
ZIKV infection is asymptomatic in most people. Only 20% of ZIKV-infected individuals develop symptoms, and in those cases, the severity of the disease varies broadly (Miner and Diamond, 2017) . Similarly, the spectrum and incidence of developmental sequelae in infants born to women infected with ZIKV during pregnancy differs within and across geographic areas, with risk estimates that range from 6%-42% (Brasil et al., 2016; Honein et al., 2017) . The biological basis for this heterogeneity is not clear. Our experiments point to a cellular and molecular explanation for how a history of DENV1 exposure could alter host responses and susceptibility to ZIKV.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Cell Lines
Human embryonic kidney HEK293-6E suspension cells were cultured at 37 C in 8% CO 2 , shaking at 120 rpm. All other cell lines described below were cultured at 37 C in 5% CO 2 , without shaking. Green monkey VERO cells and human hepatocytes Huh-7.5 cells (Blight et al., 2002) were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 1% nonessential amino acids (NEAA) and 5% FBS. Human Lenti-X 293T cells (Clontech) and STAT1
À/À
, an SV40 large T antigen immortalized skin fibroblast line (Chapgier et al., 2006) , were grown in DMEM 10% FBS. Bacteria E. coli BL21(DE3) were cultured at 37 C, shaking at 250 rpm. MC1061 cells were cultured in LB medium, with 250 rpm shaking, at 30-37 C depending on the plasmid.
Viruses
Zika virus (ZIKV), 2015 Puerto Rican PRVABC59 strain (Lanciotti et al., 2016) 
METHOD DETAILS
Collection of Human Samples Samples of peripheral blood for serum or mononuclear cells (PBMCs) isolation were obtained from community participants and donors and frozen at the cohorts' sites. PBMCs were purified using the gradient centrifugation method with Ficoll and cryopreserved in 90% heat-inactivated fetal bovine serum (FBS) supplemented with 10% dimethylsulfoxide (DMSO), prior to shipment to Rockefeller University in liquid nitrogen. Serum aliquots were heat-inactivated at 56 C for 1 hr and stored at 4 C thereafter.
Production and Biotinylation of Flavivirus Protein
The coding sequences for the EDIII portion of flaviviruses were preceded by sequences encoding the human CD5 signal peptide (MPMGSLQPLATLYLLGMLVASCLG) and followed by a polyhistidine-AviTag (HHHHHH-GLNDIFEAQKIEWHE Gene synthesis was by Genscript. The proteins were produced by transient transfection into HEK293-6E cells using PEI (polyethylenimine, branched). After 7 days of incubation, cell supernatants were cleared by centrifugation and histidine-tagged proteins were purified with Ni Sepharose 6 Fast Flow. Purified ZEDIII was biotinylated using the Biotin-Protein Ligase-BIRA kit according to manufacturer's instructions.
ELISA Assays Serum and Recombinant Antibody
The binding of serum IgG or recombinant IgG antibodies to the EDIII proteins was measured by standard ELISA. ELISA plates were coated with 250 ng of EDIII protein in PBS per well and stored overnight at room temperature. Plates were then blocked with 1% BSA, 0.1 mM EDTA in PBS-T (PBS with 0.05% Tween20) for 1 hr at 37 C. Plates were washed with PBS-T in between each step. Serum samples were diluted 1:500 with PBS-T and added for 1 hr at 37 C. Secondary HRP-conjugated goat anti-human IgG (0.16 mg/ml) was added for 1 hr at 37 C. Plates were then developed using ABTS substrate and read at 405 nm. The relative binding affinity of recombinant monoclonal antibodies was determined similarly, using serially diluted samples. The half effective concentration (EC 50 ) needed for maximal binding was determined by non-linear regression analysis. Cross-reactivity ELISA The binding of monoclonal antibodies to the panel of flavivirus EDIII proteins was determined using the standard ELISA setup described above. Antibodies were tested at 10 mg/mL alongside a control serum weakly cross-reactive to all flaviviruses. Samples with a relative optical density ratio of > 1 compared to control were deemed reactive. Auto-and Polyreactivity ELISA To determine the auto-and polyreactivity of recombinant antibodies, ELISA plates were coated with 50 mL PBS containing dsDNA (10 mg/mL), ssDNA (10 mg/mL, obtained by denaturing dsDNA at 95 C for 30 min), LPS (10 mg/mL), Insulin (5 mg/mL), or keyhole limpet hemocyanin (KLH; 10 mg/ml). After washing with PBS-T, plates were blocked with 1% BSA and 0.5 mM EDTA in 0.05% PBS-T for 2 hr at room temperature. Serial dilutions of antibody samples were then incubated for 2 hr, also at room temperature. Incubation with secondary antibody and ELISA development were performed as described above. Previously reported antibodies ED38 (Wardemann et al., 2003) and mG053 (Yurasov et al., 2005) were used as positive and negative control, respectively. Competition ELISA Competition ELISA was performed as described above for serum EDIII binding, with the following modifications. After 1 hr of incubation with serum (diluted 1:10 in PBS-T) at room temperature, biotinylated antibody Z004 (biotin-Z004) was added at a final concentration of 0.16 mg/mL to compete for an additional 15 min at room temperature. After washing, streptavidin-HRP was used for detection of bound biotin-Z004. The optimal concentration of biotin-Z004 (0.16 mg/ml) was determined by measuring its binding to ZEDIII over a range of concentrations, and corresponds to 50% of the observed maximal binding. The concentration of Z004 blocking antibodies in serum was estimated by interpolation with a standard curve generated by competing biotin-Z004 (0.16 mg/mL) with a range of non-biotinylated Z004 concentrations, and using the stats package nls() function in R 3.3.2.
Antibody Discovery and Production
Isolation of ZEDIII + Memory B Cells B cell purification, labeling, and antibody discovery were performed as previously described in detail (Tiller et al., 2008; von Boehmer et al., 2016) , with the following modifications. PBMCs were resuscitated and washed in 37 C RPMI. To enrich for B cells, PBMCs were incubated with CD19 microbeads according to the manufacturer's instructions. Upon washing, B cells were positively selected using LS magnetic columns, washed with PBS 3%FBS, and incubated with anti-CD20-PECy7, anti-IgG-APC, and fluorescently labeled ZEDIII bait at 4 C for 20 min. The fluorescently labeled ZEDIII bait was previously prepared by incubating 2-3 mg of biotin-ZEDIII with streptavidin-PE for at least 1 hr at 4 C in the dark. After wash, single CD20 + ZEDIII + IgG + memory B cells were sorted into 96-well plates using a FACSAriaII (Becton Dickinson).
Antibody Sequencing and Production
RNA from single cells was reverse-transcribed using random primers (von Boehmer et al., 2016) , followed by nested PCR amplifications and sequencing using the primers listed in (Tiller et al., 2008) . V(D)J gene segment assignment and determination of the CDR3 sequences were with IgBlast (Ye et al., 2013) . Sequences that were non-productive, out of frame, or with premature stop codons were excluded. Similarly, sequences for which a matching light or heavy chain sequence was not identifiable were omitted. Cloning for recombinant antibody production was by the Sequence and Ligation-Independent Cloning (SLIC; (Li and Elledge, 2007) ) method as detailed in (von Boehmer et al., 2016) . Amplicons from the first sequencing PCR reaction were used as template for amplification with the SLIC-adapted primers listed in Table S3 , and cloned into IGg1-, IGk-or IGl-expression vectors as detailed in (von Boehmer et al., 2016) . The recombinantly expressed antibodies correspond to the folIowing antibody sequence IDs (see Tables S1 and S2) : Z028 (MEX84_p4-53), Z001 (MEX18_21), Z004 (MEX18_89), Z006 (MEX105_42), Z010 (MEX105_88), Z031 (BRA112_46), Z035 (BRA112_71), Z038 (BRA12_2), Z014 (MEX18_91), Z039 (BRA12_21), Z015 (MEX84_p2-44), Z018 (MEX84_p2-45), Z021 (MEX84_p4-23), Z024 (MEX84_p4-12), Z012 (MEX105_57), Z037 (BRA112_57), Z041 (BRA138_57), Z042 (BRA138_17), Z043 (BRA138_15). The variable portion of the predicted germline antibody Z004-GL was codon-optimized, synthesized by Genscript, and cloned as described above (IGH 5 0 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGTCTTGTTCAGCCGGGTGGATCATTGAGAC TTTCTTGTGCTGCAAGTGGATTTACTTTCTCTTCCTACGCCATGTCTTGGGTTCGACAAGCTCCAGGGAAAGGACTCGAATGGGTTA GTGCGATATCTGGGTCTGGAGGATCTACTTACTACGCAGATTCAGTAAAAGGGCGCTTCACAATATCACGCGATAATTCCAAGAAT ACGCTCTACCTTCAGATGAACAGTCTTCGGGCAGAGGACACAGCGGTTTATTATTGTGCGAAAGATCGCGGTCCCAGAGGCGTGG GCGAACTGTTCGACTATTGGGGACAAGGCACCCTGGTCACCGTCTCCTCAG and IGK 5 0 GACATCCAGATGACCCAGTCACCGTC TACCTTGTCAGCGTCAGTTGGTGACCGGGTAACCATTACTTGCCGCGCTAGTCAGAGTATTTCCTCCTGGCTCGCCTGGTATCAAC AAAAACCAGGTAAAGCCCCCAAATTGCTGATCTATAAGGCAAGTAGCTTGGAATCAGGAGTTCCCAGCCGCTTCTCTGGCTCAGGG TCCGGTACTGAATTTACATTGACCATCTCTTCTCTCCAGCCAGATGACTTCGCCACGTACTATTGTCAACAGTATAACTCATATCCC TGGACTTTTGGACAGGGGACCAAGGTGGAAATCAAAC). Recombinant antibodies were produced as previously described (Klein et al., 2014) . Briefly, HEK293-6E cells were transiently transfected with equal amounts of immunoglobulin heavy and light chain expression vectors. After 7 days, the supernatant was harvested and antibodies were purified with Protein G Sepharose 4 Fast Flow. For antibody biotinylation, 1.5 mg/mL of Z004 were used with FluoReporter Mini-biotin-XX Protein Labeling Kit as instructed by the manufacturer.
Mouse Experiments
All experiments involving mice were performed under protocols approved by the Rockefeller University Institutional Animal Care and Use Committee. 125 mg of monoclonal antibodies in 200 mL of PBS were administered intraperitoneally to 3-4 week old IFNRA À/À mice one day prior or after infection with 1.25 3 10 5 PFU ZIKV Puerto Rican strain in 50 mL into the footpad. Mice were monitored for symptoms and survival over time.
Virus Titration Viral titers were measured on VERO cells by plaque assay (PA) for ZIKV virus and focus forming assay (FFA) for DENV-1 strains. For PA, 200 mL of serial 10-fold virus dilutions in OPTI-MEM were used to infect 400,000 cells seeded the day prior in a 6-well format. After 90 min adsorption, the cells were overlayed with DMEM containing 2% FBS with 1.2% Avicel and Pen/Strep. Four days later the cells were fixed with 3.5% formaldehyde and stained with crystal violet for plaque enumeration. For FFA, 100 mL of serial 10-fold virus dilutions in OPTI-MEM were used to infect 250,000 cells seeded the day prior in a 12-well format. After 90 min, the cells were overlayed as described above for PA. Six to 7 days later the cells were fixed and incubated with 2 mg/mL of antibody Z004 in PBS/5% FBS/0.25% Triton X-100 for 1 hr at room temperature. Foci were enumerated after reaction with goat anti-human IgG HRP-conjugated antibodies and TrueBlue HRP substrate, followed by addition of a few drops of DAB buffer solution (DAKO). Experiments with infectious ZIKV and DENV strains were performed in a biosafety level 2 laboratory.
Plaque Reduction Neutralization Test
Antibody neutralization activity was measured using a standard plaque reduction neutralization test (PRNT) on VERO cells. Diluent medium consisted of medium 199 (Lonza) supplemented with 1% BSA and Pen/Strep (BA-1 diluent). Briefly, 3-to 10-fold serial human antibody dilutions were added to a constant amount of Huh-7.5-ZIKV stock diluted in BA-1 diluent and incubated for 1 hr at 37 C prior to application to VERO cells seeded at 400,000 cells per 6-well the day prior. After 90 min adsorption at 37 C the cells were overlayed as per PA protocol above. After 4 days at 37 C, the wells were fixed and stained to enumerate plaques. PRNT 50 values were determined as the antibody concentration that resulted in 50% of the number of plaques obtained with the no antibody control.
RVP Plasmid Construction
West Nile virus (WNV) subgenomic replicon-expressing plasmid pWNVII-Rep-REN-IB and a ZIKV C-prM-E expression plasmid (pZIKV/HPF/CprME) were obtained from Ted Pierson (NIH). Plasmid pWNVII-Rep-REN-IB encodes a Renilla luciferase-expressing WNV replicon RNA while pZIKV/HPF/CprME encodes the structural proteins (C-prM-E) of the ZIKV French Polynesian strain H/PF/2013, both under the control of a CMV promoter. Co-transfection of the two plasmids into permissive cells allows the WNV replicon RNA to replicate, express luciferase and be packaged by the ZIKV H/PF/2013 structural proteins to generate
